AVITA Medical Inc

NASDAQ:RCEL

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.